Crossject SA
PAR:ALCJ

Watchlist Manager
Crossject SA Logo
Crossject SA
PAR:ALCJ
Watchlist
Price: 1.95 EUR -2.11% Market Closed
Market Cap: €103.5m

Crossject SA
Net Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Crossject SA
Net Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
Crossject SA
PAR:ALCJ
Net Income
-€11.3m
CAGR 3-Years
0%
CAGR 5-Years
-9%
CAGR 10-Years
-7%
Guerbet SA
PAR:GBT
Net Income
-€112.7m
CAGR 3-Years
-40%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Affluent Medical SAS
PAR:AFME
Net Income
-€14.7m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Crossject SA
Glance View

Market Cap
103.5m EUR
Industry
Health Care

Crossject SA manufactures and markets needle-free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject’s first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The firm has industrial partnerships with Hirtenberger and Recipharm.

ALCJ Intrinsic Value
2.78 EUR
Undervaluation 30%
Intrinsic Value
Price €1.95

See Also

What is Crossject SA's Net Income?
Net Income
-11.3m EUR

Based on the financial report for Jun 30, 2025, Crossject SA's Net Income amounts to -11.3m EUR.

What is Crossject SA's Net Income growth rate?
Net Income CAGR 10Y
-7%

Over the last year, the Net Income growth was -7%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett